- H30 -

AIMHI Accelerator Fund Too many scientific breakthroughs are left on the laboratory bench instead of being translated into nextgeneration cancer treatments. This is largely due to the lack of seed funding for earlystage oncology startups the socalled Valley of Death during which investment is too risky for traditional VCs and pharmaceutical companies. AIMHI Accelerator Fund bridges the gap from bench to bedside by providing the funding that others wont. Moreover we have inspired a broad network of coinvestors who believe in our programs and invest in these earlystage oncology and STEM companies.